Literature DB >> 25302781

Genetic variation in transmembrane 6 superfamily member 2 and the risk of nonalcoholic fatty liver disease and histological disease severity.

Silvia Sookoian1, Gustavo O Castaño, Romina Scian, Pablo Mallardi, Tomas Fernández Gianotti, Adriana L Burgueño, Julio San Martino, Carlos J Pirola.   

Abstract

UNLABELLED: We explored the role of transmembrane 6 superfamily member 2 (TM6SF2) rs58542926 C/T nonsynonymous (p.Glu167Lys) variant in genetic susceptibility to nonalcoholic fatty liver disease (NAFLD) and disease severity. A total of 361 individuals (135 control subjects and 226 patients with histologically proven NAFLD) were included in a sample with 97% power for the additive genetic model. A discrete trait analysis of NAFLD showed that rs58542926 was associated with a modest risk of fatty liver (P = 0.038; odds ratio [OR]: 1.37; 95% confidence interval [CI]: 1.02-1.84); nevertheless, conditioning on patatin-like phospholipase domain-containing 3 (PNPLA3)-rs738409 abolished this effect. We did not observe an interaction between rs738409 and rs58542926 variants on the risk of NAFLD. We observed a significant association of rs58542926 and disease severity (P = 0.027), but not lobular inflammation or fibrosis; rs58542926 was not associated with levels of liver enzymes. An allelic test showed that the T (Lys167) allele was significantly associated with disease progression (P = 0.021; OR, 1.66; 95% CI: 1.08-2.55). A significant association was found with the histological degree of liver steatosis (β, 0.15; standard error: 0.06; P = 0.0299) that was independent of rs738409. Homozygous carriers of the C (Glu167) allele showed increased risk for cardiovascular disease. TM6SF2 protein expression was decreased markedly in liver of NAFLD patients, compared to controls. In addition, TM6SF2 immunoreactivity was reduced in subjects carrying at least one copy of the T allele, consistent with a difference in liver allele-specific transcript abundance.
CONCLUSION: rs58542926 is a low-frequency variant with a modest effect on NAFLD, suggesting that carriers of the T allele are slightly more likely to accumulate fat in the liver and develop nonalcoholic steatohepatitis than those without. TM6SF2 appears to play a significant role in disease biology.
© 2014 by the American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25302781     DOI: 10.1002/hep.27556

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  78 in total

Review 1.  Genetic background in nonalcoholic fatty liver disease: A comprehensive review.

Authors:  Fabio Salvatore Macaluso; Marcello Maida; Salvatore Petta
Journal:  World J Gastroenterol       Date:  2015-10-21       Impact factor: 5.742

2.  Association of Adiponectin gene polymorphisms and nonalcoholic fatty liver disease.

Authors:  Hong-Jue Li; Chang-Ping Li; Chao Zhang; Xiao-Lin Zhong; Lei Shi
Journal:  Int J Clin Exp Med       Date:  2015-09-15

3.  Associations of TM6SF2 167K allele with liver enzymes and lipid profile in children: the PANIC Study.

Authors:  Anna Viitasalo; Jussi Pihlajamäki; Jussi Paananen; Mustafa Atalay; Virpi Lindi; Timo A Lakka
Journal:  Pediatr Res       Date:  2016-01-12       Impact factor: 3.756

Review 4.  Genetic and epigenetic mechanisms of NASH.

Authors:  Mohammed Eslam; Jacob George
Journal:  Hepatol Int       Date:  2015-12-18       Impact factor: 6.047

Review 5.  Genetic factors that affect nonalcoholic fatty liver disease: A systematic clinical review.

Authors:  Tyler J Severson; Siddesh Besur; Herbert L Bonkovsky
Journal:  World J Gastroenterol       Date:  2016-08-07       Impact factor: 5.742

Review 6.  Liver enzymes, metabolomics and genome-wide association studies: from systems biology to the personalized medicine.

Authors:  Silvia Sookoian; Carlos J Pirola
Journal:  World J Gastroenterol       Date:  2015-01-21       Impact factor: 5.742

Review 7.  Fibrosis Assessment in Nonalcoholic Fatty Liver Disease (NAFLD) in 2016.

Authors:  Dharmesh H Kaswala; Michelle Lai; Nezam H Afdhal
Journal:  Dig Dis Sci       Date:  2016-03-26       Impact factor: 3.199

Review 8.  Genetics of alcoholic liver disease and non-alcoholic steatohepatitis.

Authors:  Emma Scott; Quentin M Anstee
Journal:  Clin Med (Lond)       Date:  2018-04-01       Impact factor: 2.659

Review 9.  Diagnosis of non-alcoholic fatty liver disease (NAFLD).

Authors:  Hannele Yki-Järvinen
Journal:  Diabetologia       Date:  2016-04-18       Impact factor: 10.122

Review 10.  Genetic Pathways in Nonalcoholic Fatty Liver Disease: Insights From Systems Biology.

Authors:  Silvia Sookoian; Carlos J Pirola; Luca Valenti; Nicholas O Davidson
Journal:  Hepatology       Date:  2020-07       Impact factor: 17.425

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.